MBio Diagnostics inks development deal with U.S. Army; VolitionRx teams up with University of Oxford to develop endometriosis biomarkers;

> MBio Diagnostics inked a three-year development contract with the U.S. Army's Walter Reed Army Institute of Research to develop a point-of-care diagnostic device for malaria. Release

> VolitionRx is teaming up with the University of Oxford to develop biomarkers for endometriosis diagnosis. Release

> The FDA rejected Aeterna Zentaris' experimental growth hormone diagnostic test, saying that the Canada-based company's trial did not meet its end goal. Story

> Genetic Technologies dismissed its patent infringement lawsuit against Agilent Technologies over technology for analyzing noncoding DNA sequences. Release

> Thermo Fisher Scientific ($TMO) priced an offering of $800 million senior notes. The company plans to use proceeds to repay debt. Release

> Almac Group rolled out a next-generation sequencing test for P53 mutations. Release

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.